Is PTPI or VINC more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Vincerx Pharma N/A -248.33% -132.73%

Which has stronger valuation and earnings, AMPE or VINC?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is AMPE or VINC more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Which has higher valuation & earnings, ARDS or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00 Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is ARDS or VINC more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Which has stronger valuation & earnings, SCPS or VINC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is SCPS or VINC more profitable?

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Which has preferable valuation & earnings, VRPX or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is VRPX or VINC more profitable?

Vincerx Pharma's return on equity of -248.33% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Vincerx Pharma N/A -248.33% -132.73%

Vincerx Pharma (VINC) Competitors

$0.01 0.00 (0.00%)

As of 10:23 AM Eastern

Compare

VINC vs. PTPI, AMPE, ARDS, SCPS, and VRPX

Should you buy Vincerx Pharma stock or one of its competitors? MarketBeat compares Vincerx Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vincerx Pharma include Petros Pharmaceuticals (PTPI), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Scopus BioPharma (SCPS), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Vincerx Pharma	N/A	-248.33%	-132.73%

In the previous week, Petros Pharmaceuticals had 2 more articles in the media than Vincerx Pharma. MarketBeat recorded 2 mentions for Petros Pharmaceuticals and 0 mentions for Vincerx Pharma. Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 8.2% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Petros Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 7 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Ampio Pharmaceuticals and Vincerx Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Aridis Pharmaceuticals has a beta of 45.1, meaning that its share price is 4,410% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Vincerx Pharma on 6 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

In the previous week, Scopus BioPharma had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vincerx Pharma. Scopus BioPharma's average media sentiment score of 0.99 beat Vincerx Pharma's score of 0.00 indicating that Scopus BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Scopus BioPharma	Positive
Vincerx Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

44.0% of Vincerx Pharma shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

Scopus BioPharma beats Vincerx Pharma on 5 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Vincerx Pharma's return on equity of -248.33% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Vincerx Pharma	N/A	-248.33%	-132.73%

Virpax Pharmaceuticals has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Summary

Vincerx Pharma beats Virpax Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VINC vs. The Competition

Export

Metric	Vincerx Pharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66K	$979.79M	$6.81B	$12.17B
Dividend Yield	N/A	4.84%	2.68%	5.90%
P/E Ratio	0.00	1.50	25.79	24.20
Price / Sales	N/A	129.09	548.63	94.36
Price / Cash	N/A	20.06	46.33	53.91
Price / Book	0.00	8.01	10.77	6.37
Net Income	-$40.16M	-$4.05M	$3.57B	$337.69M
7 Day Performance	N/A	0.56%	3.15%	-0.30%
1 Month Performance	N/A	1.25%	2.34%	0.37%
1 Year Performance	N/A	47.34%	33.41%	26.93%

Vincerx Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-74.4%	$66K	N/A	N/A	60
PTPI Petros Pharmaceuticals	N/A	$0.01 +23.3%	N/A	-81.3%	$231K	$5.11M	N/A	20	News Coverage Gap Up
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+300.0%	$128K	N/A	0.03	30	Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+100.0%	$17K	N/A	N/A	9	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vincerx Pharma (VINC) Competitors

VINC vs. PTPI, AMPE, ARDS, SCPS, and VRPX

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Summary

How does Vincerx Pharma compare to Virpax Pharmaceuticals?

Summary

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vincerx Pharma (VINC) Competitors

VINC vs. PTPI, AMPE, ARDS, SCPS, and VRPX

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Is PTPI or VINC more profitable?

Does the media favor PTPI or VINC?

Which has stronger valuation & earnings, PTPI or VINC?

Do insiders & institutionals hold more shares of PTPI or VINC?

Which has more volatility & risk, PTPI or VINC?

Summary

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Which has stronger valuation and earnings, AMPE or VINC?

Is AMPE or VINC more profitable?

Does the media refer more to AMPE or VINC?

Which has more volatility and risk, AMPE or VINC?

Do institutionals and insiders hold more shares of AMPE or VINC?

Summary

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Is ARDS or VINC more profitable?

Does the media favor ARDS or VINC?

Which has higher valuation & earnings, ARDS or VINC?

Which has more volatility & risk, ARDS or VINC?

Do institutionals & insiders have more ownership in ARDS or VINC?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Is SCPS or VINC more profitable?

Does the media refer more to SCPS or VINC?

Which has stronger valuation & earnings, SCPS or VINC?

Do institutionals & insiders believe in SCPS or VINC?

Which has more risk & volatility, SCPS or VINC?

Summary

How does Vincerx Pharma compare to Virpax Pharmaceuticals?

Do insiders and institutionals hold more shares of VRPX or VINC?

Does the media prefer VRPX or VINC?

Is VRPX or VINC more profitable?

Which has more volatility and risk, VRPX or VINC?

Which has preferable valuation & earnings, VRPX or VINC?

Summary

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools